Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Prime Medicine Inc (PRME)

Prime Medicine Inc (PRME)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 7, 7:00AM CST

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease GlobeNewswire - Sun Dec 7, 2025

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
Prime Medicine to Present at Jefferies Global Healthcare Conference GlobeNewswire - Tue Nov 11, 2025

CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Fri Nov 7, 2025

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --  -- Nominated PM647...

PRME : 3.27 (-1.80%)
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Fri Nov 7, 2025

-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --  -- Nominated PM647...

PRME : 3.27 (-1.80%)
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer GlobeNewswire - Mon Nov 3, 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy GlobeNewswire - Thu Oct 30, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
Prime Medicine to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Oct 7, 2025

CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies,...

PRME : 3.27 (-1.80%)
Image of Cathie Wood via Wikimedia Commons
Why Cathie Wood is Loading Up on These 2 Growth Stocks (And Should You?) Barchart - Mon Sep 15, 2025

These two companies fit the type of transformative growth story Cathie Wood seeks out.

ARKW : 123.79 (-0.53%)
ARKG : 28.81 (-3.55%)
RBRK : 50.20 (-7.31%)
PRME : 3.27 (-1.80%)

Barchart Exclusives

NVDA Earnings, Tariffs and Other Key Things to Watch this Week Barchart - Sun Feb 22, 12:00PM CST
Markets enter a critical week dominated by Wednesday's Nvidia earnings and escalating geopolitical tensions as rising U.S.-Iran hostilities push oil prices higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot